Fibrocell Science Inc

Fibrocell Science — Investor Presentation (November 2017)

21 slides from Fibrocell Science's investor presentation, Nov 15, 2017

  1. Slide 1: Corporate Presentation November 15, 2017

    Corporate Presentation November 15, 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward- looking statements for this p

  3. Slide 3: Fibrocell at a Glance

    Proprietary autologous fibroblast cell capabilities + Ex vivo genetic modification of patients’ own fibroblast cells FCX-007 Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013 Moderate to Severe Localized Scleroderma Arthritis and related conditions 3 Fibrocell at a Glance Personalized medica

  4. Slide 4: Our Autologous Fibroblast Gene Therapy Platform

    Autologous fibroblasts harvested from patients • Readily sourced, as fibroblasts are the most common cell type in skin and connective tissue • Reduced rejection and immunogenicity concerns because the donor is the patient • Established manufacturing process and regulatory pathway for autologous fibr

  5. Slide 5: Personalized Biologics Approach

    Personalized Biologics Approach 5

  6. Slide 6: Development Pipeline

    Development Pipeline 6 Program Condition Target Research Pre-Clinical Development Human Clinical Trials FCX-007 Recessive Dystrophic Epidermolysis Bullosa (RDEB) Type VII Collagen FCX-013 Moderate to Severe Localized Scleroderma MMP-1 Research Arthritis and Related Conditions TBD

  7. Slide 7: FCX-007 Providing Hope for RDEB Patients

    FCX-007 Providing Hope for RDEB Patients 7 RDEB patients do not produce type VII collagen (COL7) due to mutation in COL7A1 gene • Main component of anchoring fibrils that connect skin layers FCX-007 is an autologous human dermal fibroblast transduced with a lentiviral (LV) vector encoded for COL7A1

  8. Slide 8: About RDEB

    About RDEB 8 Disease Current Treatments Epidemiology • Cause: A mutation in the COL7A1 gene that encodes for COL7 • Devastating, progressive, painful blistering disease that often leads to death • Diagnosed at infancy • High mortality rate – 76% of RDEB patients do not live past their 30’s1 • Curren

  9. Slide 9: Functional COL7 Expression Confirmation

    Functional COL7 Expression Confirmation 9 Culture supernatant evaluated for in vitro COL7 expression • ELISA assay indicates virus dose-dependent protein expression • Trimeric form of COL7 produced by RDEB patient fibroblasts transduced with LV-COL7 •Must be trimeric to be functional Reference: Bruc

  10. Slide 10: Treating Underlying Pathology of RDEB

    RDEB Patient’s Non-Transduced Fibroblasts • RDEB patients lack COL7A1 gene that plays critical role forming anchoring fibrils & providing integral stability to skin • In vitro studies show production of functional trimeric structure COL7 which RDEB patients lack capability to produce • In vivo studi

  11. Slide 11: FCX-007 Phase 1/2 Clinical Trial Design

    FCX-007 Phase 1/2 Clinical Trial Design 11 Title A Phase 1/2 Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) NCT02810951 Primary Objective To evaluate the safety of a single intradermal injection session of FCX-007 Sec

  12. Slide 12: FCX-007 Interim Data Readout

    FCX-007 Interim Data Readout • Interim readout of data for three NC1+ adult Phase 1 patients, 12 weeks post- administration • Single injection session of FCX-007 to target wounds or preliminary safety assessment • Five wounds treated over three patients; wounds ranged from 4.4cm2 to 13.1cm2 • FCX-00

  13. Slide 13: FCX-007 Interim Readout: Wound Healing

    FCX-007 Interim Readout: Wound Healing • Digital images captured and tracings performed  Skin tattoos and transparent overlays used as landmarks •Wounds monitored in the study prior to dosing were open at each monitoring visit up to 8 months • Compared to the baseline measurement collected at Day 0

  14. Slide 14: FCX-007 Interim Readout: Pharmacology

    FCX-007 Interim Readout: Pharmacology 14Texas Red – C7/fNC1 + DAPI + FITC – laminin 332Texas Red – C7/fNC1 • Variable pharmacology signals detected throughout the data set in each patient for one or more assays through 12 weeks post-administration (qPCR, electron microscopy, immunofluorescence)  An

  15. Slide 15: Manufacturing Experience and Solutions

    Fibrocell’s existing cGMP cell therapy manufacturing facility in Exton, PA has been designated as the production site for FCX-007 after incorporation into the IND • ~13,000 square foot facility includes:  Cleanroom for cell culture manufacturing  On-site quality control testing laboratories  Cryo

  16. Slide 16: FCX-013 Development Progressing

    FCX-013 Development Progressing 16 • Product profile  Autologous fibroblasts genetically modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), a protein responsible for breaking down collagen  Target protein known to breakdown collagens  Incorporates Intrexon’s RheoSwitch

  17. Slide 17: Localized Scleroderma Disease Epidemiology

    Localized Scleroderma 17 Disease Epidemiology • Excess production of collagen characterized by skin fibrosis and scars • Focus on moderate to severe subtypes, including linear • Thickening may extend to underlying tissue and muscle in children which may impair growth in affected limbs or forehead •

  18. Slide 18: FCX-013 Proof-of-Concept Study

    FCX-013 Proof-of-Concept Study 18 • Study Design  Bleomycin treated SCID mouse model  N=30 mice over test and control groups  Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence of FCX-013 and oral ligand • Result  Bleomycin treatment resulted in skin

  19. Slide 19: Research Program for Arthritis

    Research Program for Arthritis 19 • Deliver therapeutic protein locally to the joint providing sustained efficacy while avoiding key side effects typically associated with systemic therapy • Combines Fibrocell’s autologous fibroblast technology with Intrexon’s cellular engineering to develop localiz

  20. Slide 20: Milestones and Financials

    Program Milestone Timing FCX-007 FDA grants Fast Track Designation January 2017 FCX-007 Phase 1/2 trial first adult patient dosed February 2017 FCX-007 DSMB recommendation (after 1 patient) May 2017 FCX-013 FDA grants Rare Pediatric Disease Designation June 2017 FCX-007 Phase 1/2 trial interim updat

  21. Slide 21: References

    References 1 Fine, J. et. al. (ed.). Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. The John Hopkins University Press, Baltimore, MD, 1999. 2 The Dystrophic Epidermolysis Research Association of America (DebRA)

Fibrocell Science — Investor Presentation (November 2017) on 6ix